PMID: 42124647
15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist-Induced Weight Loss.
Nalbandian Minas, Lone Jameel, Le Moal Emmeran et al.
bioRxiv : the preprint server for biology · 2026
Research Library
Semaglutide
240 papers indexed
PMID: 42572918
A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
Goryanin Igor, Damms Bob, Goryanin Irina
CPT: pharmacometrics & systems pharmacology · 2026
PMID: 42575845
AI Patient Support and 6-Month Medication Adherence in a Digital Obesity Program: A Retrospective Analysis.
Talay Louis, Xu Connie, Alderete John et al.
Diabetes, obesity & metabolism · 2026
PMID: 42486853
AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models.
Saigal Ashmita, Abdurrachim Desiree, Tso Emily et al.
Nature communications · 2026
PMID: 42330703
ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations.
Godzo Hrisanta, Deconinck Eric, Vanhee Celine et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2026
PMID: 42541373
Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription.
Sedensky Ava, Nuzi Klaus, Nolan Laura et al.
Public health reports (Washington, D.C. : 1974) · 2026
PMID: 42292814
Activation of GLP-1R ameliorates alcohol withdrawal induced anxiety-like behavior by regulating neuronal mitochondrial quality control.
Wang Ziqi, Zhao Wei, Chen Xiaofei et al.
Frontiers in pharmacology · 2026
PMID: 42489869
Advances in proteomics research related to semaglutide: evidence from humans and animals.
Jia Qiannan, Mu Hua, Wang Yuqing et al.
Journal of endocrinological investigation · 2026
PMID: 42328491
Aesthetic Use of Poly-L-Lactic Acid and Hyaluronic Acid Fillers in Medication-Driven Weight Loss Due to GLP-1 Receptor Agonists: Real-World Case Series from Latin America.
Avelar Luiz E T, Sarlos Priscilla, Guarnieri Christine et al.
Clinical, cosmetic and investigational dermatology · 2026
PMID: 42550908
AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice.
d'Ávila Mateus, Cavalcanti-de-Albuquerque João, Collado-Pérez Roberto et al.
Proceedings of the National Academy of Sciences of the United States of America · 2026
PMID: 42380920
Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.
Yang Qian, Hassan Waseem, Ahmed Hammad et al.
BMC ophthalmology · 2026
PMID: 42291047
Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study.
Smolderen Kim G, Mena-Hurtado Carlos, Divino Victoria et al.
American journal of preventive cardiology · 2026
PMID: 42424619
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.
Frey Connor, Etminan Mahyar
Obstetrics and gynecology · 2026
PMID: 42543696
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.
Saito Chiaki, Saito Masahiro, Nakagawa Masatoshi et al.
Internal medicine (Tokyo, Japan) · 2026
PMID: 42381378
BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.
AlTaweel Muneera, Alshaikh Husain Mareyah, Rashid AlSubaiee Maram et al.
Current medical research and opinion · 2026
PMID: 42125318
Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide.
Israel Ariel, Moed Mahmud, Abo Fanne Hala et al.
Frontiers in nutrition · 2026
PMID: 42296503
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Damen Johanna A A, Idema Demy L, Vernooij Robin W M et al.
Annals of internal medicine · 2026
PMID: 42496290
Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity.
Boroghină Steluța Constanța, Arhire Amalia-Ioana, Papuc Teodora et al.
Medicines (Basel, Switzerland) · 2026
PMID: 42208956
Beyond weight loss: multisystem benefits of obesity medications.
Savas Mesut, Kuckuck Susanne, Boon Mariëtte R et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42388883
Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study.
Kapan Ali, Moser Othmar, Felsinger Richard et al.
Frontiers in endocrinology · 2026
PMID: 42414233
Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study.
Cigaina Valerio, Saggioro Alfredo, Fabris Paolo et al.
Journal of laparoendoscopic & advanced surgical techniques. Part A · 2026
PMID: 42251856
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Rosenstock Julio, Billings Liana K, Gajria Reena et al.
Lancet (London, England) · 2026
PMID: 42251859
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
Buse John B, Bajaj Harpreet S, Dalskov Stine-Mathilde et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42251858
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
Scheen André J
The lancet. Diabetes & endocrinology · 2026
PMID: 42485519
Can semaglutide influence tumor biomarkers? Insight from a clinical case.
Schianchi Alice, Mauri Fabio, Polli Christian
Journal of food and drug analysis · 2026
PMID: 42295649
Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.
Mian Muhammad Hamid Siddique, Janahi Kholood Abdulla Hasan Abdulla, Tayeb Afnan et al.
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
PMID: 42211143
Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.
Terui Sakiko, Minami Taichi, Nakamura Keita et al.
Journal of lipid and atherosclerosis · 2026
PMID: 42489387
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
Azzam Ahmed Y, Essibayi Muhammed Amir, Rai Pranjal et al.
JACC. Advances · 2026
PMID: 42575344
Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes.
Dziewierz Artur, Kulicka Natalia, Łupina Krzysztof et al.
Diabetes research and clinical practice · 2026
PMID: 42294355
Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.
Ulrich Franziska S, Frost Nielsen Morten, Napoli Nicola et al.
The Lancet regional health. Europe · 2026
PMID: 42209204
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
Wachiraphansakul Nuttaya, Vongchaiudomchoke Thanawat, Manosroi Worapaka et al.
Diabetes, obesity & metabolism · 2026
PMID: 42211533
Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications.
Baba Azhar Hafiz, Akhtar Rameez, Rawat Anurag et al.
Nepal journal of epidemiology · 2026
PMID: 42419792
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Nong Kailei, Shi Qingyang, Xie Xinran et al.
BMJ (Clinical research ed.) · 2026
PMID: 42376874
Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.
Qadeer Abdul, Khalid Marwah Bintay, Syed Ridwan et al.
Diabetes & vascular disease research · 2026
PMID: 42495930
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Wei Yuxuan, Gong Yuanyuan, Gong Jingjing et al.
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026
PMID: 42414642
Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss.
Rahman Eqram, Michon Alain, Rao Parinitha et al.
Aesthetic plastic surgery · 2026
PMID: 42469143
Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Zhou Xiao-Yu, Deng Chen-Hao, Zhong Ji-Yuan et al.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026
PMID: 42579270
Correction: Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.
Afentou Nafsika, Hall James, Ogwulu Chidubem Okeke et al.
Obesity surgery · 2026
PMID: 42484827
Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.
Afentou Nafsika, Hall James, Okeke Ogwulu Chidubem et al.
Obesity surgery · 2026
PMID: 42296505
Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
Jenniskens Kevin, Huis In 't Veld Linde F, Lokerse Marle E et al.
Annals of internal medicine · 2026
PMID: 42288971
Current trends in semaglutide therapy and strategies to improve its bioavailability.
Nayak Swasthik, Dessai Akanksha D, Nayak Usha Y
Expert opinion on drug delivery · 2026
PMID: 42211692
DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.
Sasset Linda, Cameron Andrew D, Sussman Carleigh et al.
Molecular therapy. Nucleic acids · 2026
PMID: 42578506
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Liu Tingting, Ren Xintian, Li Yanchen et al.
Journal of enzyme inhibition and medicinal chemistry · 2026
PMID: 42544568
Development and validation of a sensitive HPLC-MS/MS method for the analysis of semaglutide in human plasma.
Tudan Christopher, Stickling Joel, Northwick Darden Emily et al.
Bioanalysis · 2026
PMID: 42252377
Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.
Builes-Montaño Carlos E, Suarez-Rodriguez Andres F, Alzate-Vinasco Maria A
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
PMID: 42331726
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Ekinci Elif I, Maldonado Sandra González, Unseld Anna et al.
Diabetes, obesity & metabolism · 2026
PMID: 42256584
Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.
Samajdar Shambo Samrat, Joshi Shashank, Saboo Banshi et al.
Diabetology international · 2026
PMID: 42168638
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
Laroche Marie-Laure, Géniaux Hélène, Jardou Manon
European journal of clinical pharmacology · 2026
PMID: 42174244
Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.
Huang Yi Shan, Wen Jingyuan, Wang Siqi et al.
Obesity surgery · 2026
PMID: 42258199
Early Generic Semaglutide in Canada-Implications for US Patients and Policy.
Tu S Sean, Kesselheim Aaron S, Tadrous Mina et al.
JAMA internal medicine · 2026
PMID: 42535667
Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.
AlTaweel Muneera O, Al Makhloof Saleh, AlKhayyal Ahmad K et al.
Expert review of cardiovascular therapy · 2026
PMID: 42424036
Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.
Huang Rong, Wang Bin
The Journal of international medical research · 2026
PMID: 42163419
Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.
Seighali Niloofar, Gholami-Chahkand Mohammad Sadra, Ebrahimzade Mandana et al.
BMC pharmacology & toxicology · 2026
PMID: 42466886
Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.
Drayne Rachel, Lyons Daniel, Kirby Brian et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
PMID: 42536519
Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.
Naz Faryal, Qaiser Fawad, Mumtaz Arif et al.
Medicine · 2026
PMID: 42162206
Effects of Agonists on Skin Quality: A Comprehensive Literature Review.
Barone Mauro, Brunetti Beniamino, D'Emilio Roberta et al.
Aesthetic plastic surgery · 2026
PMID: 42140745
Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis.
Eisa Naseem, Barood Omar
Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
PMID: 42173109
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.
Helsted Mads M, Fonnesbech-Wulff Christiane, Schaltz Nina L et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42497473
Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.
Sobral Milene Vitória Sampaio, Menechini Rodrigo Bettanim, Marçal Jordana Belgamasco Cavalcanti et al.
Schizophrenia research · 2026
PMID: 42337824
Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Kaur Rashpinder, Singh Avtar
Diabetes, obesity & metabolism · 2026
PMID: 42387310
Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).
Strojek Krzysztof, Liebl Andreas, Mumbaikar Neha Narendra et al.
Diabetes, obesity & metabolism · 2026
PMID: 42495484
Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
Aljulajil Faisal A, Rabbani Unaib
Cureus · 2026
PMID: 42426564
Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.
Sun Wen-Ting, Liu Rui-Xing, Jiang Yao-Hao et al.
Diabetes, obesity & metabolism · 2026
PMID: 42253408
Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus.
Sharma Prabhat Kumar, Viswaprasad V, Choudhary Animesh et al.
Metabolism open · 2026
PMID: 42251860
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Aroda Vanita R, Buzzetti Raffaella, Dalskov Stine-Mathilde et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42575111
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.
Guo Lixin, Bao Xiaolei, Huang Kuo-Chin et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42456707
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
Loomba Rohit, George Jacob, Castera Laurent et al.
The lancet. Gastroenterology & hepatology · 2026
PMID: 42297758
Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations.
Sagar Gyan, Stránská Veronika, Stránská Denisa et al.
Diabetes, obesity & metabolism · 2026
PMID: 42334973
Erratum.
Obesity facts · 2026
PMID: 42133868
Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.
Wang Annie L, Bach Laura, Leiman David A
Journal of clinical gastroenterology · 2026
PMID: 42495454
Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.
Teli Brij, Sathe Sunil, Kalra Ravi et al.
Cureus · 2026
PMID: 42286992
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.
Rubino Domenica, Wharton Sean, Knight Michael G et al.
Postgraduate medicine · 2026
PMID: 42165732
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
Gupta Monika, Shukla Jitendra
The Indian journal of medical research · 2026
PMID: 42467193
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.
Kozato Akio, Patel Suhani S, Orandi Babak J et al.
Surgical endoscopy · 2026
PMID: 42390988
Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice.
Rout Subhasmita, Karasawa Takuya, Watanabe Shinya et al.
Diabetes · 2026
PMID: 42575231
First Approval of Semaglutide for MASH in India: A Paradigm Shift in MASLD Management?
Ezhilarasan Devaraj, Sharmila Muthusethupathi
Drug discovery today · 2026
PMID: 42124949
Food-drug interactions of novel drugs used in cardiologic and diabetic patients - a PRISMA scoping review.
Pawłowska Iga, Kuźbicka Karolina, Kowalczys Anna et al.
Frontiers in pharmacology · 2026
PMID: 42124784
GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes.
Ko Chang Seok
Journal of metabolic and bariatric surgery · 2026
PMID: 42552238
GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
Inamine Susumu, Uesato Yasunori
Diabetes, obesity & metabolism · 2026
PMID: 42331284
GLP-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: Insights from a Pilot Implementation Program.
Mirna Gerges, Carly Nichols, Kenzie MacDuff et al.
Canadian journal of diabetes · 2026
PMID: 42298156
GLP-1 Receptor Agonists in Aesthetic Surgery: A Narrative Review on Perioperative Safety, Sarcopenic Morphologies, and Adapted Body Contouring Strategies.
Venza Mario, Venza Isabella
Aesthetic plastic surgery · 2026
PMID: 42254823
GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes.
Amorim Moreira Alves Gabriel, Teranishi Masatoki, Majumdar Rajendranandini et al.
Chronic diseases and translational medicine · 2026
PMID: 42122936
GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review.
Abedi Malak Moones, Patni Mohamedanas Mohamedfaruk, Shajahan Arshiya Nasreen Bint et al.
Journal of clinical medicine · 2026
PMID: 42461204
GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.
Jerlhag Elisabet
Biological psychiatry · 2026
PMID: 42414609
GLP-1 medications: use and interest in a representative survey of Finns.
Jallinoja Piia Tuuli, Pietiläinen Kirsi H, Chang Virginia W
International journal of obesity (2005) · 2026
PMID: 42252247
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
Hsu A H-C, Ramirez P T, Chang Y-H et al.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026
PMID: 42217849
GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis.
Rai Pranjal, Bathla Girish, Praveen Niharika et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026
PMID: 42215399
GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.
Parekh Rushin S, Inban Pugazhendi, Thai Andy et al.
Disease-a-month : DM · 2026
PMID: 42546112
GLP-1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications.
Avram George M, Indelli Pier Francesco, Violante Bruno et al.
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2026
PMID: 42171681
GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review.
Wang Xuejia, Lu Guangzhen, Zhou Yingxue et al.
Journal of endocrinological investigation · 2026
PMID: 42425087
GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.
Yang Zhe, Li Xin, Wu Niujian et al.
Stem cell reports · 2026
PMID: 42572056
GLP-1-Based Therapies in Pain Medicine: A Narrative Review and Expert Opinion on Obesity-Related Low Back and Knee Pain.
Hasoon Jamal, Nguyen Anvinh, Viswanath Omar et al.
Current pain and headache reports · 2026
PMID: 42419304
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways.
Lindquist Peter, Dijkhof Luuk R H, Drzazga Anna K et al.
Cell chemical biology · 2026
PMID: 42210885
GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
Vu Marie, Schmidt Madelyn, Gandhi Smiti et al.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
PMID: 42208070
Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure.
Yu Yang, Li Xintong, Groth Susan W et al.
Obstetrics and gynecology · 2026
PMID: 42543940
Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India.
Saxena Abhyuday, Prakash Anupam
The Journal of the Association of Physicians of India · 2026
PMID: 42292722
Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis.
Muller Ferreira Vicky, Ayres Muller Victor
Cureus · 2026
PMID: 42133988
Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation.
Fallot Lucas B, Anderson Carol A, Pinc Johnathan R et al.
Journal of the American Chemical Society · 2026
PMID: 42571802
Glucagon-Like Peptide-1 Receptor Agonists and Related Incretin Therapies in Dermatology: Patient Selection and Shared Decision-Making.
Ndubisi Somto, Lio Peter
Clinics in dermatology · 2026
PMID: 42132708
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.
DeParis Sarah W, Oke Isdin, Gaier Eric D et al.
Ophthalmology · 2026
PMID: 42165084
Glucagon-like peptide-1 receptor agonists for weight loss in end-stage heart failure patients considered for heart transplantation.
Jeyakumar Sambavan, Jeyakumar Ragavi, Eckford Hunter et al.
JHLT open · 2026
PMID: 42420255
Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.
Kishi Taro, Ikuta Toshikazu, Sakuma Kenji et al.
Translational psychiatry · 2026
PMID: 42384167
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a bibliometric analysis of global research trends and research hotspots from 2006 to 2025.
Bi Qinsheng, Zhang Liangyi, Zhang Jiaxin et al.
Naunyn-Schmiedeberg's archives of pharmacology · 2026
PMID: 42131335
Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.
Ciancio Giovanni, Maranini Beatrice, Sandri Gilda et al.
Frontiers in immunology · 2026
PMID: 42467949
Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.
Haidar Lara, Delaney Joseph A C
Current opinion in HIV and AIDS · 2026
PMID: 42388962
Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.
Domingues Catarina, Ferreira Maria, Pinho Rosa
Cureus · 2026
PMID: 42171706
Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma.
Taşkaldıran Işılay, Gökbulut Püren, Yiğit Hasan et al.
Acta diabetologica · 2026
PMID: 42338042
Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.
Wharton Sean, Stefanski Adam, Chen Jiaxun et al.
Diabetes, obesity & metabolism · 2026
PMID: 42485041
Hormonal Contraception and Initiation of Semaglutide Therapy.
Bager Mille Dybdal, Wood-Kurland Hannah Karin, Sørensen Kathrine Kold et al.
JAMA network open · 2026
PMID: 42487660
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Nejat Cameron, Lin Robert, Addo Daniel et al.
Clinical case reports · 2026
PMID: 42536323
Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.
Pisani Davide, Lorenza Driul, Fordellone Mario et al.
Endocrine · 2026
PMID: 42166309
ICER report demonstrates both the value and challenges in financing of weight loss medications.
Ramachandran Sujith, Urick Ben, Thomas Tara
Journal of managed care & specialty pharmacy · 2026
PMID: 42216891
IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy.
Mi Baojing, Ding Shengjie, Tian Ziyu et al.
Bioconjugate chemistry · 2026
PMID: 42383941
Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.
Sanghvi Mihir M, Nicholls Hannah L, Kaplan Thomas M et al.
Journal of the American College of Cardiology · 2026
PMID: 42493728
Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.
Cassataro Giuliano, Scriffignano Silvia, Geraci Giulio et al.
Internal and emergency medicine · 2026
PMID: 42138385
Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort.
Ma Jimmy, Ruderman Stephanie A, Haidar Lara et al.
AIDS (London, England) · 2026
PMID: 42126155
Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
Anderson Brady J, Van Daele Douglas J, Claussen Alexander D et al.
The Annals of otology, rhinology, and laryngology · 2026
PMID: 42546302
In alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk.
Rose Mat, ACP Journal Club Editorial Team at McMaster University
Annals of internal medicine · 2026
PMID: 42455418
Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
Khatami Seyedhesamoddin, Faghihi Mohammadsadegh, Tavakoli Ghazal et al.
Cardiovascular toxicology · 2026
PMID: 42382865
Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control.
Hemdev Vaishnavi, Abuzenah Mohammad, Alsaafin Qossay et al.
Cureus · 2026
PMID: 42466348
Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.
Qiu Libin, Liu Jinpeng, Hu Nana
Frontiers in endocrinology · 2026
PMID: 42386418
Incretin-based therapies and altered myocardial metabolism in a swine model of ischemic heart disease in the setting of metabolic syndrome.
Zheng Clark, Muir Kelsey, Reddy Riya et al.
Surgery · 2026
PMID: 42299163
Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Makhmutov Alisher, Qureshi Faisal
Cureus · 2026
PMID: 42332016
LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis.
Zhao Qiurong, Chen Linxin, Xie Sha et al.
International journal of obesity (2005) · 2026
PMID: 42340790
Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.
Elganyny Mohamed Kamal ElSayed, Elganyni Abdelhakim Kamal ElSayed, Maskji Hib Alla et al.
La Clinica terapeutica · 2026
PMID: 42578314
MAFLD/MASLD: Past, Present, and Future.
Wong Vincent Wai-Sun
Journal of gastroenterology and hepatology · 2026
PMID: 42541628
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice.
Li Sainan, Toutoungy Michel, Patel Janvi et al.
Current hypertension reports · 2026
PMID: 42469146
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.
Bilato Claudio, Baratta Roberto, De Luca Leonardo et al.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026
PMID: 42301877
Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.
Ohri Smriti, Waterman Emily, Quiñones Ana R
American family physician · 2026
PMID: 42131979
Methyl Proton Spin Relaxation ( R 2 / R 1 ) Enables Sensitive Detection of pH-Dependent Oligomerization in GLP-1 Analogs.
Lu Jiaqi, Pang Eric, Chen Kang
Analytical chemistry · 2026
PMID: 42570682
Microfluidic-assisted formulation of hydrophobic ion pairing-Based solid lipid nanoparticles for semaglutide delivery.
Arduino Ilaria, Iacobazzi Rosa Maria, Pontrelli Alessia et al.
International journal of pharmaceutics · 2026
PMID: 42382663
Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.
Simancas-Racines Daniel, Campuzano-Donoso Martín, Rossetti Gianluca et al.
Obesity pillars · 2026
PMID: 42484993
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Ryszkiewicz Piotr, Baranowska-Kuczko Marta, Malinowska Barbara et al.
Pharmacological reports : PR · 2026
PMID: 42467532
N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.
Zhao Li-Hua, He Qian, Yuan Qingning et al.
Cell reports · 2026
PMID: 42420795
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.
Chen Solomon Chih-Cheng, Wang Tso-Jen, Chou Chu-Kuang et al.
Diabetes, obesity & metabolism · 2026
PMID: 42175595
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
Kamrul-Hasan A B M, Khalil Ibrahim, Mahajan Kunal et al.
Endocrinology, diabetes & metabolism · 2026
PMID: 42329656
Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.
Wan Ke-Wen, Lei Evander Fung-Chau, Liu Ying et al.
JAMA pediatrics · 2026
PMID: 42250076
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Altés Andreu, Moreno-Pérez Óscar, Sastre-Belío Miquel et al.
Advances in therapy · 2026
PMID: 42139026
Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.
The Medical letter on drugs and therapeutics · 2026
PMID: 42424303
Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.
Miller Luke B, Dellen Matthew J, Gilbert Ester J et al.
Military medicine · 2026
PMID: 42327337
Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity.
Rajamoorthi Ananthi, Hollingsworth Taylor, Guan Yuxia et al.
bioRxiv : the preprint server for biology · 2026
PMID: 42573674
Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients.
Topçu Utkan, Oto Ferhat
Journal of endocrinological investigation · 2026
PMID: 42466921
Peripheral artery disease: advances in medical therapy.
Garagoli Fernando, Slipczuk Leandro, Shapiro Michael D et al.
European heart journal · 2026
PMID: 42487666
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
La Vignera Sandro, Condorelli Rosita A
Journal of the Endocrine Society · 2026
PMID: 42296496
Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).
Qaseem Amir, Cross J Thomas, Harrod Curtis S et al.
Annals of internal medicine · 2026
PMID: 42418179
Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
Stogios Nicolette, Agarwal Sri Mahavir, Maksyutynska Kateryna et al.
JAMA psychiatry · 2026
PMID: 42421259
Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.
Chan Wah-Kheong, Leung Hak-Keith, Tan Guo-Jeng et al.
Journal of obesity & metabolic syndrome · 2026
PMID: 42389271
Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.
Yang Yu, Wang Kan
Frontiers in pharmacology · 2026
PMID: 42388893
Plant-Based Nutrition Alleviates Gastrointestinal Symptoms and Enhances Protein Intake during GLP-1 Therapy.
Withrow Nicole A, Hsueh Esther E, Wolever Thomas et al.
Current developments in nutrition · 2026
PMID: 42534203
Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.
Patel Henna, Babli Shimul A, Shah Shivani et al.
Cureus · 2026
PMID: 42467450
Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.
DiStefano Michael J, Tilley Adeleine, Paratane Deepika et al.
JAMA health forum · 2026
PMID: 42131512
Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis.
Ghosal Samit, Sinha Binayak
European heart journal open · 2026
PMID: 42575862
Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment.
Acharya Mahip, Thakur Deboleena
Diabetes, obesity & metabolism · 2026
PMID: 42327970
Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report.
Sato Manaka, Takemura Riku, Yuki Masahiro et al.
Journal of clinical medicine research · 2026
PMID: 42169198
Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.
Al-Jarshawi Mustafa, Cole Andrew, Bagur Rodrigo et al.
Cardiovascular diabetology. Endocrinology reports · 2026
PMID: 42256775
Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report.
Quarenghi Massimo, Stanga Anastasia, Bergamaschi Alessia
Journal of the American College of Emergency Physicians open · 2026
PMID: 42333387
Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies.
Rho Seungsoo, Williams Pete A
Drug design, development and therapy · 2026
PMID: 42544560
Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.
Smith Webb A, Kim Ahlee, Khalil Timothy J et al.
Childhood obesity (Print) · 2026
PMID: 42256457
Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention.
Heinberg Leslie J, Lee Alexandra M, Foster Gary D et al.
Obesity science & practice · 2026
PMID: 42383938
Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.
Ghusn Wissam, Fansa Sima, Tama Elif et al.
Mayo Clinic proceedings · 2026
PMID: 42420793
Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.
Skandov Mie Dyberg, Christensen Katrine McLain, Dalin Dagmar Abelone et al.
Diabetes, obesity & metabolism · 2026
PMID: 42543796
Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.
Thorsteinsdottir Sigrun, Jonsdottir Berglind, Olafsdottir Anna S et al.
Pediatric obesity · 2026
PMID: 42417199
Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.
Bloomgarden Zachary
Journal of diabetes · 2026
PMID: 42166306
Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.
Baalmann Angela, Michel Jakub, Avedissian Sean N et al.
Journal of managed care & specialty pharmacy · 2026
PMID: 42335260
Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.
Spitery Allison, Lobkovich Alison, Thomas Emily
The American journal of managed care · 2026
PMID: 42388102
Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.
Verma Raj, Verma Meena, Park Brady et al.
Current opinion in cardiology · 2026
PMID: 42340212
Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.
Leah Oana-Monica, Leaşu Florin G, Badea Mihaela et al.
American journal of therapeutics · 2026
PMID: 42217114
Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey.
Arnaut Timothy, Duncan Shannon, Faurby Mads et al.
Advances in therapy · 2026
PMID: 42414781
Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer.
Muscogiuri Giovanna, Del Vecchio Guendalina, Colangeli Luca et al.
Internal and emergency medicine · 2026
PMID: 42551699
Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.
Dutta Deep, Jena Sweekruti, Mahajan Kunal et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
PMID: 42541759
Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms.
Rajan Lakshmipriya Thandiyekkal, Hofland Johannes, Mulugeta Eskeatnaf et al.
European journal of endocrinology · 2026
PMID: 42208060
Safety, tolerability and efficacy of GLP-1 receptor agonists (GLP-1 RA) in the management of post-liver transplant weight gain: A multicenter, observational study.
Khan Mohammad Qasim, Becchetti Chiara, Jouid Mahmoud Riyam et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026
PMID: 42217600
Semaglutide Use in Patients Undergoing Atrial Fibrillation Ablation and Recurrent Arrhythmia: A Focused Time-to-Event Meta-analysis.
Abomohsen Mustafa, Mohamed Ahmed Elmorsy, Almakadma Abdul Hakim et al.
Heart rhythm · 2026
PMID: 42381999
Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition.
Lin Junming, Luo Mengliang, Tang Huaxin et al.
Journal of orthopaedic translation · 2026
PMID: 42126676
Semaglutide ameliorates neuroinflammation and cognitive impairment in APP/PS1 mice.
Yuan Yuan, Zhang Jiawei, Zhang Ziyao et al.
Molecular and cellular biochemistry · 2026
PMID: 42542232
Semaglutide ameliorates traumatic sepsis-induced cardiac injury by activating the March5-ACSL4 axis to suppress ferroptosis.
Sun Baisheng, Liu Lingxin, Zhang He et al.
Free radical biology & medicine · 2026
PMID: 42297743
Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials.
Chiang Cho-Han, Bahar Furkan, Chang Yu-Cheng et al.
Diabetes, obesity & metabolism · 2026
PMID: 42339050
Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis.
Li Yanhua, Lv Chunmei, Cao Lianlian et al.
Biomedical reports · 2026
PMID: 42257166
Semaglutide and weight loss in obese patients with and without type 2 diabetes.
Gupta Harish, Verma Rajeev
Journal of family medicine and primary care · 2026
PMID: 42573665
Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities.
Mukim Rijuta Dhanraj, Xu Yama, Evola Vito et al.
Molecular biology reports · 2026
PMID: 42571323
Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.
Jiménez-Mausbach Martí, Tijms Betty M, Paterson Clare et al.
Alzheimer's & dementia (Amsterdam, Netherlands) · 2026
PMID: 42174184
Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons.
Gao Claire, Geneve Isabelle C, Rodriguez-Gonzalez Shakira et al.
Nature metabolism · 2026
PMID: 42334436
Semaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation.
Malik Farheen, Shah Mandar, Chang Yu et al.
European heart journal. Cardiovascular pharmacotherapy · 2026
PMID: 42493207
Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.
Vanlaer Yana, Embo Nina, Bochanen Niels et al.
BMJ open · 2026
PMID: 42543936
Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.
Jha Ajay Kumar, Sunder Ashok
The Journal of the Association of Physicians of India · 2026
PMID: 42384388
Semaglutide in Schizophrenia-A Top Clinical Trial.
Öngür Dost
JAMA psychiatry · 2026
PMID: 42214023
Semaglutide in metabolic dysfunction-associated alcohol-related liver disease: a potential dual-target therapy for metabolic dysfunction and alcohol use.
Nery Filipe
European journal of gastroenterology & hepatology · 2026
PMID: 42210124
Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study.
Jin Chao-Lun, Huang Lu, Wei Ying-Ying et al.
BMC cardiovascular disorders · 2026
PMID: 42336886
Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism.
Guo Yunchong, Su Junlei, Shen Lijun et al.
Scientific reports · 2026
PMID: 42540132
Semaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection.
Matson Robert, Venkatakrishnan A J, Murugadoss Karthik et al.
Biology methods & protocols · 2026
PMID: 42174253
Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Stanley Chloe, Mallik Ritwika, Hamid Nausheen et al.
Nature medicine · 2026
PMID: 42464447
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
Cannon Ethan J, Wang Wendy, Norby Faye L et al.
British journal of clinical pharmacology · 2026
PMID: 42128321
Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.
Allen Matthew R, Metzger Corinne E, Chen Neal X et al.
Bone · 2026
PMID: 42466220
Semaglutide-Induced Ischemic Colitis in A Middle-Aged Female Without Vascular Risk Factors.
Joma Marwan, Karam Abdulrahman M, Sayeh Wasef et al.
European journal of case reports in internal medicine · 2026
PMID: 42545324
Semaglutide-Induced Sarcopenia via GLP-1R-mTOR-Satellite Cells Axis and Muscle-Glucose Feedback Loop Potentially Leading to Refractory Hyperglycemia in Type 2 Diabetes: A Case-Driven Hypothesis.
Ahmed Amr, Rodini Sharifa, Alrubyea Fahad et al.
Problemy endokrinologii · 2026
PMID: 42166479
Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.
Chrzanowski Jędrzej, Walicka Magdalena, Burzyński Jacek et al.
PLoS medicine · 2026
PMID: 42254092
Semaglutide-induced lean mass loss: clinical concern or physiological adaptation.
Qaseem Muhammad, Ahmad Naveed, Haider Ehtisham et al.
Annals of medicine and surgery (2012) · 2026
PMID: 42420782
Short-Term HbA1c Non-Inferiority of Synthetic Semaglutide Should Not Be Conflated With Full Therapeutic Interchangeability.
Singh Awadhesh Kumar, Singh Akriti, Singh Ritu
Diabetes, obesity & metabolism · 2026
PMID: 42170981
Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.
Long Wang, Ningning Li, Weijun Huang
Pakistan journal of pharmaceutical sciences · 2026
PMID: 42579768
Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography.
Li Jiahui, Wu Hao, Glaser Kevin J et al.
Hepatology communications · 2026
PMID: 42423951
Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.
Pendrey Anna Geraldina, Rivera Sierra Jennyfer Alejandra, Alvarez Lobo Fernando Alberto et al.
Advances in therapy · 2026
PMID: 42253285
Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide.
Olson Thomas E, Lloyd Trevor S, Hamad Christopher D et al.
JOR spine · 2026
PMID: 42291462
Spontaneous Pneumomediastinum Associated with Semaglutide Therapy: A Case Report.
Diebold Johanna, Gubler Christoph, Murray Fritz Ruprecht
Case reports in gastroenterology · 2026
PMID: 42297449
The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.
De Riddhita, Amin Alfatwa Yasser, Kanagasundaram Pruntha et al.
Schizophrenia bulletin · 2026
PMID: 42297754
The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.
Eisa Naseem, Khoury Mira
Diabetes, obesity & metabolism · 2026
PMID: 42337822
The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies.
Overgaard Rune Viig, Agersø Henrik, Hollensen Christian et al.
Diabetes, obesity & metabolism · 2026
PMID: 42419462
The Neuroendocrine-Appetite-Mental Health Triangle in PMOS: Implications for GLP-1 Receptor Agonist Therapy.
Xu Wenting, Lu Chao, Xu Jie et al.
Neuroscience and biobehavioral reviews · 2026
PMID: 42166683
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms.
Davies Iona, Holst Jens J, Rosenkilde Mette M et al.
Annual review of nutrition · 2026
PMID: 42210891
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
Zarabian Nikkia, Farah Mina, Stines Amanda et al.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
PMID: 42462869
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
Ravindhran Bharadhwaj, Chetter Ian, Pymer Sean
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2026
PMID: 42487380
The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East.
Albukhari Abdullah Faisal
Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit · 2026
PMID: 42339860
The systems medicine view of semaglutide: from clinical trials to molecular mechanisms.
Vitorino Rui
Expert review of clinical pharmacology · 2026
PMID: 42468029
Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: Retraction.
Batool Suhayya
Retina (Philadelphia, Pa.) · 2026
PMID: 42486217
Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.
Klausen Mette Kruse, Fink-Jensen Anders
Biological psychiatry · 2026
PMID: 42499082
Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.
Khan Suleman, Jamal Asad, Qadri Maria et al.
Medicine · 2026
PMID: 42460324
Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.
Kahkedjian Fredy, Shah Jaffer, Kreidieh Firas
Frontiers in endocrinology · 2026
PMID: 42128641
Top studies of 2025 relevant to primary care: From the PEER team.
Moe Samantha S, Perry Danielle, Thomas Betsy S et al.
Canadian family physician Medecin de famille canadien · 2026
PMID: 42124020
Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.
Pineda-Wieselberg Ronaldo José, Soares Andressa Heimbecher, Napoli Thiago Fraga et al.
Nutrients · 2026
PMID: 42213650
Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.
Kim Young Chul, Meng Chen, Kanoo Sadhana et al.
American journal of physiology. Renal physiology · 2026
PMID: 42211780
Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis.
Guimarães Gabriela N F
Case reports in medicine · 2026
PMID: 42464889
Trends in Usage and Payments for Glucagon-Like Peptide-1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross-Sectional Study.
Hammond Michael M, Krishnan Vaishnavi, Petito Lucia C et al.
Journal of the American Heart Association · 2026
PMID: 42570295
Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia.
Belančić Andrej, Kučan Štiglić Marta, Fajkić Almir et al.
The Journal of international medical research · 2026
PMID: 42294499
Turning back time: a comprehensive list of interventions that decrease next-generation epigenetic aging clocks in humans.
Johnson Adiv A, Sinclair David A
Frontiers in genetics · 2026
PMID: 42255432
Type B insulin resistance with glycemic extremes: a case report and literature review.
Ngo Emmeline Monique T, Rowe Jordan M, Chillon Thilo Samson et al.
Frontiers in endocrinology · 2026
PMID: 42137313
Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance.
Zinzi Alessia, Gaio Mario, Ruggiero Rosanna et al.
Frontiers in pharmacology · 2026
PMID: 42465136
Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.
Khalil Waqas, Bibi Khadija, Fareed Tauheed et al.
Cureus · 2026
PMID: 42252120
Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025.
Kildegaard Helene, Andersen Jacob Harbo, Vinding Rebecca Kofod et al.
Obesity (Silver Spring, Md.) · 2026
PMID: 42250233
Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review.
Horne Michael Paul, Pollard Hannah, Day Heather et al.
Journal of the American Association of Nurse Practitioners · 2026
PMID: 42457940
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.
Lee Hyeong Min, Marakkalage Kamindu Gayashan, Kim Sang Hyo et al.
International journal of obesity (2005) · 2026
PMID: 42297751
Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort.
Liu Shuang, Cao Baige, Lin Chuwen et al.
Diabetes, obesity & metabolism · 2026
PMID: 42252045
Weight Loss Associated with Semaglutide Use is Linked to Improved Reproductive Measures in PMOS: a Proof-Of-Concept Analysis.
Cree Melanie G, Garcia-Reyes Yesenia, Shapiro Allison et al.
Fertility and sterility · 2026
PMID: 42209262
Weight Management With Semaglutide and Tirzepatide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk.
Choi Hailey, Hwang Andrew Y
Diabetes, obesity & metabolism · 2026
PMID: 42382138
Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.
Gillikin Andrew, Lee Yung, Varney Catherine et al.
EClinicalMedicine · 2026
PMID: 42163990
Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network.
Murugadoss Karthik, Varma Gowtham, Venkatakrishnan A J et al.
Biology methods & protocols · 2026
PMID: 42485552
When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.
Emanuele Enzo, Minoretti Piercarlo, Ballerio Martina et al.
Fundamental & clinical pharmacology · 2026
PMID: 42214359
[Advances in Anti-Dementia Therapies in Older Adults].
Schnieder Marlena, von Arnim Christine
Deutsche medizinische Wochenschrift (1946) · 2026
PMID: 42536830
[An historical overview of GLP-1/GIP incretins. From hormone to "swiss-army knife" medications].
Portha Bernard
Biologie aujourd'hui · 2026
PMID: 42169518
[Glucagon-like peptide-1 agonists and heart failure].
Soborun Nisha, Favre Lucie, Lu Henri et al.
Revue medicale suisse · 2026
PMID: 42390457
[Insulin intoxications caused by falsified semaglutide].
Stammers Julian, Hofste Op Bruinink Davine, Karel Peter G A et al.
Nederlands tijdschrift voor geneeskunde · 2026
PMID: 42545321
[Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].
Troshina E A, Antsiferov M B, Ametov A S et al.
Problemy endokrinologii · 2026
For research use only. This index links to third-party literature. Nothing here constitutes medical advice.